N-Pyrazinylhydroxybenzamides As Biologically Active Compounds: A Hit-Expansion Study and Antimicrobial Evaluation

References

• Prestinaci F , PezzottiP , PantostiA. Antimicrobial resistance: a global multifaceted phenomenon. Pathog. Glob. Health109(7), 309–318 (2015).
   PubMed Web of Science ®Google Scholar
• Murray CJL , IkutaKS , ShararaFet al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet399(10325), 629–655 (2022).
   PubMed Web of Science ®Google Scholar
• Miethke M , PieroniM , WeberTet al. Towards the sustainable discovery and development of new antibiotics. Nat. Rev. Chem.5(10), 726–749 (2021).
   PubMed Web of Science ®Google Scholar
• Darby EM , TrampariE , SiasatPet al. Molecular mechanisms of antibiotic resistance revisited. Nat. Rev. Microbiol.21(5), 280–295 (2023).
   PubMed Web of Science ®Google Scholar
• WHO . Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including TuberculosisWHO, Geneva, Switzerland (2017).
   Google Scholar
• Chalmers SJ , WylamME. Methicillin-resistant Staphylococcus aureus infection and treatment options. Methods Mol. Biol.2069, 229–251 (2020).
   PubMedGoogle Scholar
• Turner NA , Sharma-KuinkelBK , MaskarinecSAet al. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat. Rev. Microbiol.17(4), 203–218 (2019).
   PubMed Web of Science ®Google Scholar
• Parlet CP , BrownMM , HorswillAR. Commensal staphycocci influence Staphylococcus aureus skin colonization and disease. Trends Microbiol.27(6), 497–507 (2019).
   PubMed Web of Science ®Google Scholar
• Liu GY . Molecular pathogenesis of Staphylococcus aureus infection. Pediatr. Res.65(5), 71R–77R (2009).
   PubMed Web of Science ®Google Scholar
• Edwards B , AndiniR , EspositoSet al. Treatment options for methicillin-resistant Staphylococcus aureus (MRSA) infection: where are we now? J. Glob. Antimicrob. Resist. 2(3), 133–140 (2014).
   PubMed Web of Science ®Google Scholar
• Shariati A , DadashiM , MoghadamMT , van BelkumA , YaslianifardS , Darban-SarokhalilD. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis. Sci. Rep.10(1), (2020).
   Web of Science ®Google Scholar
• Cong Y , YangS , RaoX. Vancomycin resistant Staphylococcus aureus infections: a review of case updating and clinical features.J. Adv. Res.21, 169–176 (2020).
   PubMed Web of Science ®Google Scholar
• WHO . Global Tuberculosis Report 2022.WHO, Geneva, Switzerland (2022). www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022
   Google Scholar
• Singh R , DwivediSP , GaharwarUS , MeenaR , RajamaniP , PrasadT. Recent updates on drug resistance in Mycobacterium tuberculosis. J. Appl. Microbiol.128(6), 1547–1567 (2020).
   PubMed Web of Science ®Google Scholar
• The Pew Charitable Trusts . Tracking the Global Pipeline of Antibiotics in Development, April 2020The Pew Charitable Trusts, PA, USA (2020). www.pewtrusts.org/en/research-and-analysis/issue-briefs/2020/04/tracking-the-global-pipeline-of-antibiotics-in-development
   Google Scholar
• Katsuno K , BurrowsJN , DuncanKet al. Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nat. Rev. Drug Discov.14(11), 751–758 (2015).
   PubMed Web of Science ®Google Scholar
• Hughes JP , ReesS , KalindjianSB , PhilpottKL. Principles of early drug discovery. Br. J. Pharmacol.162(6), 1239–1249 (2011).
   PubMed Web of Science ®Google Scholar
• Zitko J , MindlováA , ValášekOet al. Design, synthesis and evaluation of N-pyrazinylbenzamides as potential antimycobacterial agents. Molecules23(9), (2018).
   PubMed Web of Science ®Google Scholar
• Sun QG , LiXJ , PerezLM , ShiWL , ZhangY , SacchettiniJC. The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD. Nat. Commun.11(1), (2020).
   Web of Science ®Google Scholar
• Boshoff HI , MizrahiV , BarryCE. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J. Bacteriol.184(8), 2167–2172 (2002).
   PubMed Web of Science ®Google Scholar
• Ngo SC , ZimhonyO , ChungWJ , SayahiH , JacobsWR , WelchJT. Inhibition of isolated mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs. Antimicrob. Agents Chemother.51(7), 2430–2435 (2007).
   PubMed Web of Science ®Google Scholar
• Sayahi H , PuglieseKM , ZimhonyO , JacobsWR , ShekhtmanA , WelchJT. Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M. tuberculosis fatty acid synthase I. Chem. Biodivers.9(11), 2582–2596 (2012).
   PubMed Web of Science ®Google Scholar
• Nawrot D , SuchankovaE , JandourekOet al. N-pyridinylbenzamides: an isosteric approach towards new antimycobacterial compounds. Chem. Biol. Drug Des.97(3), 686–700 (2021).
   PubMed Web of Science ®Google Scholar
• Dolezal M , KesetovicD , ZitkoJ. Antimycobacterial evaluation of pyrazinoic acid reversible derivatives. Curr. Pharm. Des.17(32), 3506–3514 (2011).
   PubMed Web of Science ®Google Scholar
• Dolezal M , ZitkoJ , KesetovicovaD , KunesJ , SvobodovaM. Substituted N-phenylpyrazine-2-carboxamides: synthesis and antimycobacterial evaluation. Molecules14(10), 4180–4189 (2009).
   PubMed Web of Science ®Google Scholar
• Zitko J , ServusovaB , PaterovaPet al. Synthesis, antimycobacterial activity and in vitro cytotoxicity of 5-chloro-n-phenylpyrazine-2-carboxamides. Molecules18(12), 14807–14825 (2013).
   PubMed Web of Science ®Google Scholar
• Kratky M , KonecnaK , BrokesovaK , MaixnerovaJ , TrejtnarF , VinsovaJ. Optimizing the structure of (salicylideneamino)benzoic acids: towards selective antifungal and anti-staphylococcal agents. Eur. J. Pharm. Sci.159, (2021).
   PubMed Web of Science ®Google Scholar
• Kratky M , VinsovaJ , NovotnaE , MandikovaJ , TrejtnarF , StolarikovaJ. Antibacterial activity of salicylanilide 4-(trifluoromethyl)benzoates. Molecules18(4), 3674–3688 (2013).
   PubMed Web of Science ®Google Scholar
• European Committee for Antimicrobial Susceptibility Testing of the European Society of Clinical Microbiology and Infectious Diseases . Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. Clin. Microbiol. Infect.9(8), ix–xv (2003).
   Web of Science ®Google Scholar
• European Committee for Antimicrobial Susceptibility Testing . EUCAST Definitive Document E.Def 7.3.2 (2020). www.eucast.org/astoffungi/methodsinantifungalsusceptibilitytesting/susceptibility_testing_of_yeasts/ (Accessed 23May2023).
   Google Scholar
• European Committee for Antimicrobial Susceptibility Testing . EUCAST Definitive Document E.Def 9.4 (2022). www.eucast.org/astoffungi/methodsinantifungalsusceptibilitytesting/ast_of_moulds (Accessed 23May2023).
   Google Scholar
• Franzblau SG , WitzigRS , McLaughlinJCet al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J. Clin. Microbiol.36(2), 362–366 (1998).
   PubMed Web of Science ®Google Scholar
• European Committee for Antimicrobial Susceptibility Testing . EUCAST reference method for MIC determination of Mycobacterium tuberculosis. www.eucast.org/mycobacteria/methods_in_mycobacteria (Accessed 23May2023).
   Google Scholar
• JAS T , RanjithaJ , RajanA , ShankarV. Features of the biochemistry of Mycobacterium smegmatis, as a possible model for Mycobacterium tuberculosis. J. Infect. Public Health13(9), 1255–1264 (2020).
   PubMed Web of Science ®Google Scholar
• Gupta RS , LoB , SonJ. Phylogenomics and comparative genomic studies robustly support division of the genus Mycobacterium into an emended genus Mycobacterium and four novel genera. Front. Microbiol.9, (2018).
   Google Scholar
• Namouchi A , CiminoM , Favre-RochexS , CharlesP , GicquelB. Phenotypic and genomic comparison of Mycobacterium aurum and surrogate model species to Mycobacterium tuberculosis: implications for drug discovery. BMC Genomics18(1), (2017).
   PubMedGoogle Scholar
• Chaturvedi V , DwivediN , TripathiRP , SinhaS. Evaluation of Mycobacterium smegmatis as a possible surrogate screen for selecting molecules active against multi-drug resistant Mycobacterium tuberculosis. J. Gen. Appl. Microbiol.53(6), 333–337 (2007).
   PubMed Web of Science ®Google Scholar
• Heinrichs MT , MayRJ , HeiderFet al. Mycobacterium tuberculosis strains H37ra and H37rv have equivalent minimum inhibitory concentrations to most antituberculosis drugs. Int. J. Mycobacteriol.7(2), 156–161 (2018).
   PubMedGoogle Scholar
• Nowakowska J , GriesserHJ , TextorM , LandmannR , KhannaN. Antimicrobial properties of 8-hydroxyserrulat-14-en-19-oic acid for treatment of implant-associated infections. Antimicrob. Agents Chemother.57(1), 333–342 (2013).
   PubMed Web of Science ®Google Scholar
• Pankey GA , SabathLD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin. Infect. Dis.38(6), 864–870 (2004).
   PubMed Web of Science ®Google Scholar
• Hoelke B , GieringerS , ArltM , SaalC. Comparison of nephelometric, UV-spectroscopic, and HPLC methods for high-throughput determination of aqueous drug solubility in microtiter plates. Anal. Chem.81(8), 3165–3172 (2009).
   PubMed Web of Science ®Google Scholar